# Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma

> **NCT05675033** · PHASE2 · UNKNOWN · sponsor: **Fujian Cancer Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Lung Adenocarcinoma
- Stage IV Non-small Cell Lung Cancer
- PD-1 Inhibitor
- VEGF

## Interventions

- **DRUG:** Serplulimab and Bevacizumab injection

## Key facts

- **NCT ID:** NCT05675033
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-10
- **Primary completion:** 2023-01-10
- **Final completion:** 2024-01-10
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05675033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05675033, "Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05675033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*